Funda Meric-Bersntam

111PUBLICATIONS
900CO-AUTHORS
Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markersCancer geneticsCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (111)

|Oct 16, 2026
Cobimetinib + Vemurafenib in Patients With BRAF V600E-Mutant Papillary Thyroid and Biliary Tract Cancers: Results From the TAPUR Study.

|Oct 07, 2026
Sunitinib in Patients With Various Solid Tumors With FGFR1/2 Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.

|Sep 22, 2026
Zanidatamab in patients with early stage HER2-positive breast cancer: the NeoZanHER phase 2 single-arm open-label trial.

|Aug 26, 2026
Molecular Response Assessment From Circulating Tumor DNA in Patients With Ovarian Cancer Treated With the WEE1 Inhibitor Azenosertib.

|Aug 18, 2026
Proteogenomic profiling identifies FGFR2b as a prevalent cell-surface target in intrahepatic cholangiocarcinoma.

|Jul 27, 2026
Clinical Impact of Mismatch Repair Gene Mutation-Based Alert on Immunotherapy Decision Making Across Patients With Cancer.

Pageof 19

Frequent Collaborators

17 joint publications

Timothy Anthony Yap

15 joint publications

Aung Naing

15 joint publications

Jordi Rodon Ahnert

12 joint publications

Siqing Fu